Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2018.
Commission File Number: 000-53805
Intellipharmaceutics International Inc.
(Translation of registrant's name into English)
30 WORCESTER ROAD TORONTO, ONTARIO M9W 5X2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ x
] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Note: Regulation S-T Rule
101(b)(1) only permits the submission in paper of a Form 6-K if
submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Note: Regulation S-T Rule
101(b)(7) only permits the submission in paper of a Form 6-K if
submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws
of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home
country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the
report or other document is not a press release, is not required to
be and has not been distributed to the registrant’s security
holders, and, if discussing a material event, has already been the
subject of a Form 6-K submission or other Commission filing on
EDGAR.
EXPLANATORY NOTE
Intellipharmaceutics
International Inc. (the “Company”) amends its report on
Form 6-K furnished to the U.S. Securities and Exchange Commission
(the “Commission”) on July 16, 2018 (the “Form
6-K”) solely to include the Interactive Data File with
respect to the unaudited condensed consolidated financial
statements included in the Form 6-K.
Except
as expressly set forth above, this amendment to the Form 6-K does
not amend, update or restate the information furnished on the Form
6-K or reflect any events that have occurred since the Form 6-K was
originally filed.
EXHIBITS TO FORM 6-K/A
|
|
|
|
|
ExhibitNumber
|
|
Description
|
|
|
|
|
101.INS
|
|
XBRL
Instance Document
|
|
101.SCH
|
|
XBRL
Schema Document
|
|
101.CAL
|
|
XBRL
Calculation Linkbase Document
|
|
101.DEF
|
|
XBRL
Definition Linkbase Document
|
|
101.LAB
|
|
XBRL
Label Linkbase Document
|
|
101.PRE
|
|
XBRL
Presentation Linkbase Document
|
This Report on Form 6-K/A is incorporated by reference into the
Company’s effective Registration Statements on Form F-3, as
amended and supplemented (Registration Statement Nos. 333-172796
and 333-218297), filed with the Commission, from the date on which
this Report is filed, to the extent not superseded by documents or
reports subsequently filed or furnished by Intellipharmaceutics
International Inc. under the Securities Act of 1933 or the
Securities Exchange Act of
1934.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
|
Intellipharmaceutics International Inc.
(Registrant)
/s/ Andrew
Patient
|
|
Date: July 24, 2018
|
|
Andrew Patient
Chief Financial Officer
|